**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.

**UKCEPTI** (UK Centre of Excellence for Precision Therapeutic Implants) is an R&D-centric venture of National and Global significance built around a core team with significant scientific, financial, and operational success in turning science into businesses**.** UKCEPTI provides a compelling opportunity to accelerate and scale R&D towards clinical applications and commercialisation of 3D 3D-engineered tissues targeting a wide variety of applications, including organ repair and drug development. UKCEPTI's patented and proven technology platform is the brainchild of Professor Hagan Bayley -- founder of Oxford Nanopore Technologies, one of the most successful spinout companies, which floated on the London Stock Exchange for $4B in 2021\. **Why Now?** By 2050, the ageing population is expected to be more than 2 billion. Ageing is a complex phenomenon; significant changes occur in our cells and tissues, resulting in diseased and damaged organs, often resulting in organ failure. Organ transplantation is a convoluted process; many people die waiting for an organ due to the lack of suitable donors. UKCEPTI's vision is to build a future where through early intervention we can repair soft organs such as the Heart, Brain, Eye, Liver, Pancreas, etc., and avoid the need for an organ transplant. By using our engineered tissues incorporating cells derived from human stem cells we will increase healthy lifespans in a novel and affordable way. Powered by compelling scientific breakthroughs, UKCEPTI will be an innovative centre of National and Global significance that will disrupt the $150 billion (by 2030) tissue engineering applications market. UKCEPTI's multidisciplinary team of researchers, clinicians, hospitals, healthcare professionals, and entrepreneurs will turn challenges into opportunities, driving prosperity and well-being across the UK and the world. UKCEPTI will build sustainable partnerships with key organisations in the supply and value chains to deliver effective solutions for the target population. UKCEPTI will benefit from Prof Hagan Bayley's 3D-engineered tissues, that offer unparalleled uniformity, quality, and the potential of seamless integration of multiple cell types whilst maintaining affordability. The high-resolution printing of living cells yields 3D tissues that have high cell viability and can be pre-patterned, functional, and can differentiate and migrate, allowing UKCEPTI to produce intricate heterogeneous structures like native human tissues. Our research is protected by more than 12 patents and patent families and will be licensed to UKCEPTI. The intellectual property portfolio provides a strong and defensible market position in the precision tissue engineering market.